Plain-English translation of NCT04896047 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are studying a natural substance in your body called FGF19, which helps control metabolism and may support muscle strength. In people with chronic kidney disease, FGF19 levels appear to be lower than normal. This study will compare FGF19 levels and muscle function in patients with kidney disease at different stages, people on dialysis, and healthy volunteers to see if there's a connection.
Muscle loss (called sarcopenia) affects about half of dialysis patients and one in five people with kidney disease, making it harder to stay active and reducing quality of life. Currently, exercise is the only proven way to combat it, but many patients cannot exercise due to other health conditions. Researchers hope understanding FGF19's role could lead to new treatments.
You likely qualify if…
You likely don't qualify if…
You will visit the research center for assessments of your muscle strength and function. The researchers will take blood samples and perform a small muscle biopsy (a tiny tissue sample taken with a needle under local anesthetic). If you are on dialysis, doctors may also take a small bone sample during a procedure you may already need for your kidney care. The study compares three groups: people with kidney disease, people on dialysis, and healthy volunteers without kidney disease.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
France